Company news

Precision BioSciences, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Precision BioSciences Reports Second Quarter 2021 Financial Results and Provides Business Update

August 11, 2021

Precision BioSciences to Report Second Quarter 2021 Financial Results on August 12, 2021

August 4, 2021

Precision BioSciences Doses First Patient in Phase 1 Allogeneic CAR T Clinical Trial of PBCAR19B Immune Evading Stealth Cell for Relapsed/Refractory Non-Hodgkin Lymphoma

June 30, 2021

Precision BioSciences Announces New Study Published in Nature Communications Using Engineered ARCUS Nuclease to Target Mutant Mitochondrial DNA In Vivo

May 31, 2021

Precision BioSciences Appoints Alex Kelly as Chief Financial Officer

May 26, 2021

Precision BioSciences Reports First Quarter and 2021 Financial Results and Provides Business Update

May 12, 2021

Precision BioSciences to Report First Quarter 2021 Financial Results on May 13, 2021

May 5, 2021

Precision BioSciences Announces Poster Presentation at the Upcoming American Society of Gene & Cell Therapy Annual Meeting

April 26, 2021

Precision BioSciences Appoints Renowned Hematologist Alan List, M.D. as Chief Medical Officer

April 14, 2021

Precision BioSciences Appoints Stanley R. Frankel, M.D. to Board of Directors

April 11, 2021

Precision BioSciences Announces CEO Transition Plan

April 5, 2021

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update

March 17, 2021

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2020 Financial Results on March 18, 2021

March 11, 2021

Precision Announces 3-Year Pre-clinical Study Results Showing Long-term Durability and Safety of ARCUS In Vivo Gene Editing to Cut LDL Cholesterol Levels in Nonhuman Primates

February 18, 2021

Precision BioSciences Receives Notice of Allowance for U.S. Patent Application Covering PBCAR19B, a Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma

January 24, 2021

Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma

January 18, 2021

Precision BioSciences Announces Closing of In Vivo Gene Editing Collaboration and License Agreement with Eli Lilly and Company

January 6, 2021

Precision BioSciences Announces Executive Leadership Change

December 13, 2020

Precision BioSciences Reports Positive Interim Results from PBCAR0191 Phase 1/2a Trial in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and R/R B-cell Acute Lymphoblastic Leukemia (B-ALL)

December 3, 2020

Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement

November 19, 2020

Precision BioSciences Reports Third Quarter 2020 Financial Results and Provides Business Update

November 9, 2020

Precision BioSciences to Report Third Quarter 2020 Financial Results on November 10, 2020

November 2, 2020

Precision BioSciences Announces U.S. Patent Trial and Appeal Board Upholds Allogeneic CAR T Patents

October 14, 2020

Precision BioSciences Appoints Alex Kelly as Chief Corporate Affairs Officer

October 13, 2020

Precision BioSciences and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma

September 20, 2020

Precision BioSciences and Servier Expand CAR T Oncology Development Collaboration with Four New Programs Targeting Hematological and Solid Tumors

September 16, 2020

Precision BioSciences Receives Fast Track Designation from U.S. Food and Drug Administration for PBCAR269A, an Investigational Allogeneic CAR T Therapy for Relapsed/Refractory Multiple Myeloma

September 8, 2020

Precision BioSciences Receives Fast Track Disease Designation from U.S. Food and Drug Administration for PBCAR0191 Investigational Allogeneic CAR T Cell Therapy

August 18, 2020

Precision BioSciences Reports Second Quarter 2020 Financial Results and Provides Business Update

August 12, 2020

Precision BioSciences Regains Rights to In Vivo Hepatitis B Virus Program

July 5, 2020

Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR269A for Multiple Myeloma

June 7, 2020

Precision BioSciences Reports First Quarter 2020 Financial Results and Provides Business Update

May 14, 2020

Precision BioSciences Announces Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting

April 27, 2020

Precision Biosciences Appoints Dora Alvarado as Senior Vice President of Human Resources

April 14, 2020

Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR20A for Relapsed/Refractory NHL, CLL, and SLL

April 6, 2020

Precision BioSciences Strengthens Board of Directors with Appointment of Geno Germano

March 10, 2020

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update

March 9, 2020

Precision BioSciences to Report Fiscal Year and Fourth Quarter 2019 Financial Results and Present at Upcoming Investor Conferences

February 20, 2020

Precision BioSciences Announces FDA Acceptance of IND for PBCAR269A, a BCMA Targeted Genome Edited Allogeneic CAR T Therapy Candidate for Multiple Myeloma

January 12, 2020

Precision BioSciences Welcomes Healthcare Industry Expert, Kevin J. Buehler, to its Board of Directors

November 12, 2019

Precision BioSciences Reports Third Quarter 2019 Financial Results and Highlights Ongoing Operational Progress Including Initial Data from PBCAR0191 Phase 1/2a Clinical Trial

November 11, 2019

Precision BioSciences Announces the Presentation of Initial Clinical Data Supporting the Safety and Clinical Activity of PBCAR0191, a Novel CD19 Targeted Allogeneic CAR T Therapy Candidate, at the American Society of Hematology Annual Meeting

November 5, 2019

Precision BioSciences Appoints Nicholas Riddle, MB, BChir, PhD, as Vice President, Financial Strategy and Investor Relations

September 29, 2019

Precision BioSciences Appoints David Thomson, PhD, as Chief Operating Officer

September 22, 2019

Precision BioSciences Announces FDA Clearance of the IND for PBCAR20A, a CD20 Targeting Genome Edited Allogeneic CAR T Therapy

September 15, 2019

← Newer news releases

Decks

The 5 newest of 52 decks. Every deck is listed under its year.